Lyell Immunopharma Inc Market Cap ($215.40 Million)
Market Cap & Net Worth: Lyell Immunopharma Inc (LYEL)
Lyell Immunopharma Inc market cap. Lyell Immunopharma Inc (NASDAQ:LYEL) has a market capitalization of $215.40 Million ($215.40 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16043 globally and #3836 in its home market, demonstrating a 15.68% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lyell Immunopharma Inc's stock price $10.77 by its total outstanding shares 24505141 (24.51 Million). Also see LYEL cash generation efficiency for how efficiently the company converts equity into cash flow.
Lyell Immunopharma Inc Market Cap History (2021–2026)
Lyell Immunopharma Inc market cap history from 2021 to 2026. Data shows change from $189.67 Million to $263.92 Million (-8.02% CAGR). Check Lyell Immunopharma Inc (LYEL) share price today for real-time trading data and today's change.
Index Memberships
Lyell Immunopharma Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #433 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1576 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.01% | #220 of 263 |
Weight: Lyell Immunopharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lyell Immunopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lyell Immunopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Lyell Immunopharma Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
20951.90x
Lyell Immunopharma Inc's market cap is 20951.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $189.67 Million | $10.65 Million | -$250.22 Million | 17.81x | N/A |
| 2022 | $85.03 Million | $84.68 Million | -$183.12 Million | 1.00x | N/A |
| 2023 | $47.54 Million | $130.00K | -$234.63 Million | 365.69x | N/A |
| 2024 | $15.68 Million | $61.00K | -$342.99 Million | 257.10x | N/A |
| 2025 | $754.27 Million | $36.00K | -$274.45 Million | 20951.90x | N/A |
Competitor Companies of LYEL by Market Capitalization
Companies near Lyell Immunopharma Inc in the global market cap rankings as of November 4, 2026. Also see Lyell Immunopharma Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Lyell Immunopharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Lyell Immunopharma Inc (2021–2026)
Market capitalization of Lyell Immunopharma Inc from 2021 to today. Between 2021 and today, Lyell Immunopharma Inc's market cap moved from $189.67 Million to $ 263.92 Million, with a yearly change of -8.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $263.92 Million | -65.01% |
| 2025 | $754.27 Million | +4709.38% |
| 2024 | $15.68 Million | -67.01% |
| 2023 | $47.54 Million | -44.09% |
| 2022 | $85.03 Million | -55.17% |
| 2021 | $189.67 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Lyell Immunopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $215.40 Million USD |
| MoneyControl | $215.40 Million USD |
| MarketWatch | $215.40 Million USD |
| marketcap.company | $215.40 Million USD |
| Reuters | $215.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in … Read more